Patents Assigned to OncoTab, Inc.
  • Publication number: 20230049618
    Abstract: Provided are antibodies, and fragments and derivatives thereof, particularly humanized derivatives thereof, which bind to tumor antigens. Also provided are nucleic acid molecules encoding chimeric antigen receptors (CARs) that bind to tumor antigens, polypeptides and CARs encoded by the nucleic acid molecules, vectors and host cells that include the nucleic acid molecules, methods of making the same, and methods for using the same to generate a persisting population of genetically engineered T cells in a subject, expanding a population of genetically engineered T cells in a subject, modulating the amount of cytokine secreted by a T cell, reducing the amount of activation-induced calcium influx into a T cell, providing an anti-tumor immunity to a subject, treating a mammal having a MUC1-associated disease or disorder, stimulating a T cell-mediated immune response to a target cell population or tissue in a subject, and imaging a MUC1-associated tumor.
    Type: Application
    Filed: August 3, 2022
    Publication date: February 16, 2023
    Applicants: The University of North Carolina at Charlotte, OncoTAb, Inc.
    Inventors: Pinku Mukherjee, Jordon Wang, Kexin Huang, Yan He
  • Patent number: 11554181
    Abstract: Provided are antibodies, and fragments, derivatives, and nanoparticle conjugates thereof, particularly humanized derivatives thereof, which bind to tumor antigens. Also provided are nucleic acid molecules encoding chimeric antigen receptors (CARs) that bind to tumor antigens, polypeptides and CARs encoded by the nucleic acid molecules, vectors and host cells that include the nucleic acid molecules, methods of making the same, and methods for using the same to generate a persisting population of genetically engineered T cells in a subject, expanding a population of genetically engineered T cells in a subject, modulating the amount of cytokine secreted by a T cell, reducing the amount of activation-induced calcium influx into a T cell, providing an anti-tumor immunity to a subject, treating a mammal having a MUC1-associated disease or disorder, stimulating a T cell-mediated immune response to a target cell population or tissue in a subject, and imaging a MUC1-associated tumor.
    Type: Grant
    Filed: September 3, 2019
    Date of Patent: January 17, 2023
    Assignees: The University of North Carolina at Charlotte, OncoTab, Inc.
    Inventors: Pinku Mukherjee, Jordon Wang, Kexin Huang, Yan He